Health ❯ Healthcare ❯ Medical Research ❯ Neurology

Alzheimer's Disease

Wide Plasma Proteomics Study Finds Distinct Blood Signals for Amyloid Clearance and Cognitive Change in Patients on Lecanemab

Validation in other clinics would allow these multi‑protein blood tests to monitor plaque removal or forecast patients' cognitive course without routine brain scans.

11 ARTICLES

3w ago

Alzheimer’s Research Enters a New Era as Trials Multiply and Diagnosis Scales Up

3 ARTICLES

last mo.

34‑circRNA Blood Signature Outperforms pTau217 in Detecting and Predicting Alzheimer’s

5 ARTICLES

3mo ago

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

3 ARTICLES

3mo ago

Glucosamine Linked to Faster Dementia Progression and Higher Death Risk, Study Finds

7 ARTICLES

4mo ago

Glucosamine Linked to Faster Progression and Higher Death Rates in Alzheimer’s Patients

16 ARTICLES

4mo ago

Blood Tests and New PET Tracer Reveal Early Alzheimer’s Signals in Some Middle‑Aged Adults

3 ARTICLES

5mo ago

Common Blood Test Marker Linked to Higher Future Dementia Risk, Large Study Finds

21 ARTICLES

5mo ago

Major Review Says New Alzheimer’s Antibodies Offer No Meaningful Benefit

5 ARTICLES

6mo ago

Blood Test Detects Alzheimer’s Risk Years Before PET Scans

3 ARTICLES

6mo ago

Dual Blood Markers Sharpen Alzheimer’s Diagnosis by Cutting False Positives

20 ARTICLES

7mo ago

Blood Test Using p‑Tau217 Predicts Dementia Risk in Women Up to 25 Years Before Symptoms

17 ARTICLES

7mo ago

Blood ‘Clock’ Predicts Alzheimer’s Symptom Onset Within 3–4 Years

7 ARTICLES

8mo ago

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

9 ARTICLES

9mo ago

Finger-Prick Blood Spot Test Detects Alzheimer’s Biomarkers With 86% Accuracy

Alzheimer's Disease

Wide Plasma Proteomics Study Finds Distinct Blood Signals for Amyloid Clearance and Cognitive Change in Patients on Lecanemab

Alzheimer’s Research Enters a New Era as Trials Multiply and Diagnosis Scales Up

FDA Clears PrecivityAD2 Blood Test for Symptomatic Adults Aged 40 and Up

New Blood Biomarkers Differentiate Alzheimer’s Risk by Disease Stage

Blood p‑tau217 Test Predicts Elevated 5‑ and 10‑Year Alzheimer’s Risk

Blood Test p‑tau217 Predicts Alzheimer Risk but Not Ready for Routine Screening

Biogen's Tau Drug Cuts Brain Tau but Misses Dose‑Response Goal

34‑circRNA Blood Signature Outperforms pTau217 in Detecting and Predicting Alzheimer’s

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

Glucosamine Linked to Faster Dementia Progression and Higher Death Risk, Study Finds

Never miss stories about

Alzheimer's Disease

Glucosamine Linked to Faster Progression and Higher Death Rates in Alzheimer’s Patients

Blood Tests and New PET Tracer Reveal Early Alzheimer’s Signals in Some Middle‑Aged Adults

Common Blood Test Marker Linked to Higher Future Dementia Risk, Large Study Finds

Major Review Says New Alzheimer’s Antibodies Offer No Meaningful Benefit

Blood Test Detects Alzheimer’s Risk Years Before PET Scans

Dual Blood Markers Sharpen Alzheimer’s Diagnosis by Cutting False Positives

Blood Test Using p‑Tau217 Predicts Dementia Risk in Women Up to 25 Years Before Symptoms

Blood ‘Clock’ Predicts Alzheimer’s Symptom Onset Within 3–4 Years

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

Finger-Prick Blood Spot Test Detects Alzheimer’s Biomarkers With 86% Accuracy

Never miss stories about

Alzheimer's Disease